ArticleProceedings of the National Academy of Sciences of the United States of America2012

T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.

Victoria Hillerdal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.